Cardinal Health, Inc (CAH) Fair Value & Analysis
Healthcare · US · Market cap $53.9B
Cardinal Health, Inc
CAH · US
Fair value as of: Aug 13, 2026
From 22 valuation models · updated yesterday
Share price +0.5% over the past month.
A solid business, but screening 39% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($183.06). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($87.93 to $183.06) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $41.53 – $240.26 · fair‑value band $87.93 – $183.06 · the $231.24 price screens above the $141.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Cardinal Health, Inc (CAH) currently trades at $231.24, while our model-based Fair Value estimate is $141.77, implying the stock looks roughly 38.7% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Cardinal Health, Inc generated revenue of $251B at a net margin of 0.6%. Revenue grew 11.0% year over year. Net debt stands at $5.5B. The stock trades on a trailing P/E of 35.4. Fundamentals as of Aug 13, 2026
Our scenario range runs from $87.93 (bear case) to $183.06 (bull case); at $231.24, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 1% below its 52-week high and 69% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at -39%, CAH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: DCF Models ($153.55) versus Dividend Discount ($33.95). Highest evidence: Growth DCF (80).
Notify me when CAH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.
Full company description
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cardinal Health, Inc reported revenue of $223B in FY2025 versus $162B in FY2021, a compound +8.2%/yr. Reported net income was $1.6B in FY2025, compounding +26.4%/yr from FY2021.
of which total revenue +8.5 pp · buybacks/dilution +3.6 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
CAH screens 39% overvalued. Compare with McKesson Corporation →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Cardinal Health (CAH) Stock Looks About Right On Earnings But Stretched On Broader Checks
- CAH Q4 Earnings Call Centers on Fiscal 2027 Growth Outlook
- Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
| China National Medicines Corporation 600511 | ¥27.35 | ¥58.22 | +113% |
Compare Cardinal Health, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cardinal Health, Inc (CAH) overvalued or undervalued?
What is the fair value of CAH?
What is the quality score of CAH?
What is the revenue of Cardinal Health, Inc (CAH)?
What is the net profit margin of CAH?
Does Cardinal Health, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cardinal Health, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.